Thromboxane A2 acts as tonic immunoregulator by preferential disruption of low-avidity CD4+ T cell–dendritic cell interactions

Federica Moalli,1 Jovana Cupovic,2 Flavian Thelen,1 Pascal Halbherr,1 Yoshinori Fukui,3,4 Shuh Narumiya,5 Burkhard Ludewig,2 and Jens V. Stein1

1Theodor Kocher Institute, University of Bern, 3012 Bern, Switzerland
2Institute of Immunobiology, Cantonal Hospital St. Gallen, CH-9007 St. Gallen, Switzerland
3Division of Immunogenetics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation and
4Research Center for Advanced Immunology, Kyushu University, Fukuoka 812-8582, Japan
5Department of Pharmacology, Faculty of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan

Interactions between dendritic cells (DCs) and T cells control the decision between activation and tolerance induction. Thromboxane A2 (TXA2) and its receptor TP have been suggested to regulate adaptive immune responses through control of T cell–DC interactions. Here, we show that this control is achieved by selectively reducing expansion of low-avidity CD4+ T cells. During inflammation, weak tetramer-binding TP-deficient CD4+ T cells were preferentially expanded compared with TP-proficient CD4+ T cells. Using intravital imaging of cellular interactions in reactive peripheral lymph nodes (PLNs), we found that TXA2 led to disruption of low- but not high-avidity interactions between DCs and CD4+ T cells. Lack of TP correlated with higher expression of activation markers on stimulated CD4+ T cells and with augmented accumulation of follicular helper T cells (Tfh), which correlated with increased low-avidity IgG responses. In sum, our data suggest that tonic suppression of weak CD4+ T cell–DC interactions by TXA2–TP signaling improves the overall quality of adaptive immune responses.

© 2014 Moalli et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months, it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

T cells have evolved to quickly react to potentially dangerous microbes by recognizing pathogen-derived peptide (p)-MHC complexes displayed on antigen-presenting cells, in particular DCs. Because T cells are selected in the thymus for their ability to recognize self-pMHC complexes (Morris and Allen, 2012) and numerous self-reactive T cells are released into the periphery (Su et al., 2013), peripheral tolerance education is critical to avoid activation of autoreactive T cells. Studies using intravital two-photon microscopy (2PM) of reactive PLNs have shed light on the dynamic T cell–DC interactions and their correlation with full versus curtailed T cell activation and tolerance induction. The amount of cognate pMHC complexes on activated DCs is critical in determining the transition of a highly motile scanning-mode T cell to an immotile, stably interacting one (Cahalan and Parker, 2006; Henrickson and von Andrian, 2007; Bajenoff and Germain, 2007). Such stable T cell–DC interactions (>8h) are a prerequisite for full effector T cell differentiation (Rachmilewitz and Lanzavecchia, 2002). Thus, in presence of high amounts of cognate pMHC on activated DCs, T cells decelerate rapidly, whereas T cells show a motile DC sampling behavior when cognate pMHC levels are low. Altered peptide ligands (APLs) with reduced affinity for a given TCR also decrease the length of T cell–DC interactions, limiting T cell activation. Under tolerogenic conditions (i.e., in the absence of co-stimulation), 2PM studies uncovered shortened T cell–DC interactions (Hugues et al., 2004) although this is still controversial (Shakhar et al., 2005). Similarly, the presence of regulatory T (Treg) cells reduces...
T cell–DC interactions and subsequent T cell activation (Tadokoro et al., 2006; Tang et al., 2006).

A perhaps counterintuitive recent finding has revealed a significant increase in CD8+ T cell immune response avidity in presence of T reg cells (Pace et al., 2012). This is due to T reg cell–mediated suppression of excessive interactions between DCs and CD8+ T cells bearing TCRs with low avidity for pMHC complexes. In the absence of T reg cells, uncontrolled CCR5 ligand secretion by activated DCs induces attraction of bystander TCR clones with low affinity for pMHC complexes, which decreases overall avidity and memory T cell generation of the resulting immune response. Whether a comparable mechanism also exists to selectively support activation of high avidity CD4+ T cells by immunoregulatory factors is currently unknown.

The short-lived arachidonic acid–derived lipid thromboxane A2 (TXA2) has been suggested to regulate adaptive immune responses (Kabashima et al., 2003). Activated DCs and other cell types produce TXA2, which binds its G-protein coupled receptor TP expressed in thymocytes and naive but not effector/memory CD4+ and CD8+ T cells. Addition of high amounts of the TP agonist 1-BOP induces chemokinesis in naive T cells and decreases in vitro aggregate formation between T cells and DCs, causing reduced T cell activation (Kabashima et al., 2003). Combined with the observation that TXA2 levels rapidly rise in reactive PLN during immune responses (Moore et al., 1989), these data suggest a model where TXA2 may act as a general suppressor of T cell–DC interactions. In line with this hypothesis, aged TP-deficient T cells develop lymphoid hyperplasia and high antibody titers (Kabashima et al., 2003)

Yet, it has remained unknown how TXA2 signaling affects dynamic CD4+ T cell interactions with DC displaying varying pMHC abundance and affinity in vivo, and how this impacts avidity patterns of responding T cells.

Here, we show that during sterile and microbial inflammation, absence of TP resulted in increased expansion of low-avidity CD4+ T cells. Using 2PM imaging of cellular interactions in reactive PLNs, we report that paracrine TXA2 signaling preferentially disrupted low-avidity interactions between DCs and OT-II CD4+ T cells induced by low cognate pMHC levels or low-affinity peptide. As a consequence, TP−/− OT-II CD4+ T cells show increased expression of early activation markers, as well as augmented accumulation of follicular helper T cells (Tfh) compared with WT OT-II CD4+ cells. High numbers of TP−/− Tfh correlated with increased low-avidity IgG production, thus thwarting the overall quality of the adaptive immune response. In sum, our data uncover a previously unappreciated contribution of a tolerance-inducing mechanism for preferential activation of high-avidity CD4+ T cells.

**RESULTS AND DISCUSSION**

**Lack of TP lowers overall polyclonal CD4+ T cell avidity during inflammation**

TP−/− mice were reported to develop lymphadenopathy and increasing circulating Ig levels with age (>26 wk; Kabashima et al., 2003). In our SPF colony, we observed enlarged mesenteric LNs (MLNs), occasionally accompanied by splenomegaly, in TP−/− mice >3 mo old (unpublished data). We therefore evaluated antigen–specific adaptive immune responses in younger WT and TP−/− mice (5–8 wk), which displayed normal lymphoid organ size and showed no signs of spontaneous lymphocyte activation (unpublished data). Because physiological T cell responses involve low- and high-avidity TCR T cells (Sabatino et al., 2011), we examined the role of TP during expansion of Ag-specific CD4+ T cells recognizing OVA-derived peptides after s.c. OVA/CFA immunization (Fig. S1 A). Both WT and TP−/− mice showed expansion of low- and high-avidity OVA-peptide tetramer-positive (OVA tet+) CD4+ T cells on day 8 after immunization in draining PLNs (Fig. 1 A). Notably, we found a larger increase of OVA tet+ CD4+ T cells in reactive PLNs of TP−/− mice as compared with WT mice (Fig. S1 B), in particular among the weak-binding OVA tet+ low population (Fig. 1 B). When we compared the ratio of low- and high-avidity OVA tet+ CD4+ T cells, we consistently found in draining PLNs relatively more low-avidity T cells participating in the immune response in TP−/− mice compared with WT mice, despite comparable TCR expression levels (Fig. 1, C and D). A recent study has implicated neutrophil-derived TXA2 in the control of T cell responses (Yang and Unanue, 2013). We therefore performed OVA/CFA immunization in neutrophil-depleted WT and TP−/− mice. Similar to nondepleted mice, TP deficiency resulted in increased expansion of low-avidity CD4+ T cells in PLNs (Fig. 1 E). To rule out an influence of different TCR repertoires in WT and TP−/− mice on expansion of low- and high-avidity CD4+ T cells, we analyzed their ratio in control versus TP antigen GR32191B-treated WT mice after s.c. OVA/CFA immunization. Again, we observed a skewing of the adaptive immune response toward low-avidity CD4+ T cells in reactive GR32191B-treated WT PLNs as compared with controls (Fig. 1 F). In two independent experiments, the ratio of low- vs. high-avidity CD4+ T cells from GR32191B-treated mice was increased by >30%.

To examine the relevance of TP-dependent tonic signaling in an infection model, we infected WT and TP−/− mice with lymphocytic choriomeningitis virus (LCMV) Armstrong strain. During LCMV Armstrong infection, we observed a nonsignificant tendency for increased expansion of gpr67−tet+ CD4+ T cells in TP−/− as compared with WT spleens (8.8 ± 3.3% in WT vs. 14.8 ± 9.1% in TP−/− mice; mean ± SD), whereas no tet+ CD4+ T cells were observed in PLNs (unpublished data). Among the gpr67−tet+ populations, the ratio of low- to high-avidity T cells was strongly skewed to the former in TP−/− mice (Fig. 1, G–I; and Fig. S1 C), despite comparable CD4+ FoxP3+ T reg cell percentages (not depicted). Collectively, the results obtained in sterile and infectious inflammation models suggest that absence of TP shapes the differential expansion of low- versus high-avidity T cells in a polyclonal repertoire.
**Brief Definitive Report**

**Figure 1.** Absent TP signaling results in enhanced expansion of low-avidity CD4+ T cells during inflammation. (A–D) WT and TP−/− mice were immunized with OVA/CFA, and OVA-specific CD4+ T cells in the draining peripheral LNs (PLNs) were analyzed on day 8 by tetramer staining. (A) Representative flow cytometry plots of polyclonal WT versus TP−/− CD4+ T cells after gating on CD4+ T cells and staining with control or OVA-specific tetramers. Numbers indicate percentage of CD4+ T cells in low and high tetramer gates. (B) Percentages of low and high OVA tetramer+ CD4+ T cells. (C) Ratio of low versus high OVA tetramer+ CD4+ T cells. (D) MFI of CD3 expression on OVA tetramer+ WT and TP−/− T cells. (E and F) Mice were depleted by injecting anti-Ly6G antibody (1A8) on day −1 (E) or mice were treated with a selective thromboxane receptor antagonist (GR32191B) for 9 d starting 1 d before immunization (F). Ratio of low versus high OVA tetramer+ CD4+ T cells in draining PLNs at day 8 are shown. (G–I) WT and TP−/− were infected with LCMV Armstrong, and CD4+ T cells in spleen were analyzed on day 8. (G) Representative flow cytometry plots of control and gp66-77 tetramer+ CD4+ T cells. Numbers indicate percentage of 7AAD− CD4+ T cells in low and high tetramer gates. (H) Percentages of low versus high gp66-77 tetramer+ CD4+ T cells. (I) Ratio of low versus high gp66-77 tetramer+ CD4+ T cells. Data in B, C, and E are pooled from two independent experiments with a total of 4–7 mice per condition and combined staining of each sample with two different OVA tetramers, whereas D and F show representative data from one of two independent experiments with comparable results (3–4 mice/group). Data in G–I are pooled from two independent experiments with a total of 8 mice/group. Data in B and H were analyzed using ANOVA with Sidak’s post-test, whereas C–F and I were analyzed using the Mann-Whitney test and are shown ±SEM. **, P < 0.01; ***, P < 0.001.

**TP expression on naive OT-II CD4+ T cells impairs in vivo interactions with DCs bearing low amounts or weak agonist pMHC complexes**

The data obtained in our inflammation models prompted us to examine how TP influenced dynamic CD4+ T cell–DC interactions in vivo. We therefore generated TP−/− OT-II CD4+ T cells recognizing the OVA_{323-339} peptide. Despite high expression of TP in thymocytes, TP−/− OT-II CD4+ T cells displayed a bona fide naive phenotype characterized by high L-selectin/low CD44 expression and CD3 levels similar to WT OT-II CD4+ T cells (unpublished data). Furthermore, WT and TP−/− OT-II CD4+ T cells formed comparable in vitro immunological synapses (IS) defined by LFA-1 and PKCθ translocation to OVA_{323-339} pulsed DCs and showed, in the absence of TP agonist I-BOP, similar proliferation and activation marker up-regulation after in vitro stimulation (unpublished data). Using these cells as tools in combination with DCs pulsed with varying OVA peptide concentrations, we performed 2PM of draining PLNs to directly investigate the effect of TXA2–TP signaling during initial T cell–DC interactions in vivo. As reported for T cell migration in explanted PLNs (Huang et al., 2007), lack of TP did not influence the speed, directionality, and motility coefficient (MC) of naive T cells as compared with WT T cells in nonreactive PLNs (Fig. 2 A and not depicted), presumably owing to low TXA2 levels in steady state. In contrast, activated DCs pulsed with 0.1 µM OVA_{323-339} induced a significantly stronger deceleration of TP−/− OT-II CD4+ T cell speeds as compared...
with WT OT-II CD4+ T cells, accompanied by an increase of the arrest coefficient and a lower MC (Fig. 2, B and C; and Video 1). This speed difference disappeared when we examined T cell motility in the presence of DCs pulsed with 10 µM OVA peptide, although TP−/− OT-II CD4+ T cells still showed an increased arrest coefficient as compared with WT OT-II CD4+ T cells (Fig. 2, B and C; Video 2).

Figure 2. Intravital imaging of WT versus TP−/− OT-II CD4+ T cell interactions with pMHC-loaded DCs. (A–E) Polyclonal WT and TP−/− T cells were adoptively transferred in the absence of s.c. injected DCs (A) or WT and TP−/− OT-II CD4+ T cells were transferred in presence of DCs pulsed with indicated OVA323-339 or turkey (t)OVA324-340 (B–E). Single cell speeds and MC of adoptively transferred cells (A and B), their arrest coefficient (C) and T cell–DC interaction times (E) were monitored by 2PM imaging. D shows representative 2PM images of DC interactions with WT (arrowheads) and TP−/− OT-II CD4+ T cells (arrows). An encircled HEV is seen in the top row. Time is shown in minutes and seconds. Bar, 10 µm. Each dot represents one track (A–C) or interaction (E). Data in A–C and E are pooled from at least two independent experiments and were analyzed by Mann-Whitney test. Red bars indicate median. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
When we analyzed the duration of T cell–DC contacts, we observed that WT OT-II CD4+ T cells engaged in mostly short interactions with DCs pulsed with 0.1 µM OVA323-339, with only 38% of observed interactions lasting >20 min (Fig. 2, D and E; and Video 3). In contrast, TP−/− OT-II CD4+ T cells engaged longer with 0.1 µM OVA323-339-pulsed DCs, with 58% of all observed interactions lasting throughout the observation period (P < 0.05). This difference was not observed when we quantified contact duration of WT and TP−/− OT-II CD4+ T cells with DCs pulsed with 10 µM OVA323-339. Under these conditions, stable interactions prevailed in both cell populations (68 vs. 73% for WT and TP−/− OT-II CD4+ T cells, respectively; Fig. 2, D and E; and Video 4). At 18–24 h after transfer, we observed that both cell populations had detached from DCs and moved with similar migration speeds, suggesting that TP mostly controls T cell–DC interactions during the first hours of contact or during initial contact formation (unpublished data).

In addition to the abundance of cognate pMHC complexes, T cell–DC interactions are regulated by TCR–pMHC affinity. To examine this further, we used APL-pulsed DCs using 10 µM turkey OVA peptide (tOVA324-340), which yields pMHC complexes with lower affinity for the OT-II TCR (Gollmer et al., 2009). In 2PM experiments, the majority of WT OT-II CD4+ T cells interacted only briefly with tOVA324-340-pulsed DCs and continued with high migration speeds and low arrest coefficient (Fig. 2, B–E; and Video 5). Absence of TP on OT-II CD4+ T cells permitted these cells to interact significantly longer with tOVA324-340-pulsed DCs (9 vs. 25% for WT and TP−/− OT-II CD4+ T cells, respectively; P < 0.01), resulting in decreased migration speeds and increased arrest coefficients (Fig. 2, B–E; and Video 6). In sum, our 2PM imaging experiments suggest a role for TP in restraining naive CD4+ T cell–DC interactions when cognate pMHC levels or TCR–pMHC affinities are low, in line with a function of cell-extrinsic tonic regulator. Tonic regulation prevents participation of naive lymphocytes in adaptive immune responses by raising the activation threshold, whereas T reg cells often act to dampen already activated T cells and are therefore considered reactive regulators in many cases (Germain, 2012).

Increased early OT-II CD4+ T cell activation and Tfh generation in the absence of TP

We examined the consequences of increased duration of TP−/− OT-II CD4+ T cell–DC interactions on effector differentiation. 24 h after transfer to recipient mice containing 0.1 µM OVA323-339-pulsed DCs, TP−/− OT-II CD4+ T cells showed increased expression of the early activation markers CD69 and CD25 as compared with WT OT-II CD4+ T cells (Fig. 3, A–C). Higher CD69 and CD25 expression was also observed in TP−/− OT-II CD4+ T cells after transfer with DCs pulsed with 10 µM OVA323-339 (Fig. 3, A–C). This suggests that TP−/− OT-II CD4+ T cells integrate signals more efficiently than TP-proficient cells over a wide range of pMHC densities. Notably, CD69 and CD25 expression levels of TP−/− OT-II CD4+ T cells stimulated by 0.1 µM OVA323-339-pulsed DCs were comparable to those of WT OT-II CD4+ T cells stimulated by 10 µM OVA323-339-pulsed DCs (Fig. 3 B), indicating that 100-fold lower pMHC levels were already sufficient to induce robust in vivo TP−/− OT-II CD4+ T cell activation. Extrapolated to a polyclonal T cell population with variable TCR repertoire, the data obtained using a monoclonal TCR population suggest that the activation threshold for TP−/− CD4+ T cells bearing low-avidity TCRs is substantially reduced as compared with WT CD4+ T cells during inflammation. Given the abundance of low-avidity T cell clones during immune responses (Sabatino et al., 2011), this likely explains the substantial expansion of low-avidity CD4+ T cells in the absence of TP signaling (Fig. 1).

High TCR binding strength results in the generation of follicular helper T cells (Tfh; Fazilleau et al., 2009), and TP−/− mice develop increased circulating antibody titers with age (Kabashima et al., 2003). We thus investigated whether the absence of TP influenced the generation of Tfh 8 d after OVA/CFA immunization in mice having received WT and TP−/− OT-II CD4+ T cells. We found that the TP−/− OT-II CD4+ T cells had expanded significantly more than WT CD4+ T cells (Fig. 4, A and B; and Fig. S1 D), whereas both cell populations differentiated similarly into CXCR5highPD-1high Tfh (Fig. 4, C and D) and showed comparable expression of bcl-6 (Fig. 4 E), IL-21 (Fig. 4 F), and ICOS (not depicted). The similar percentage of Tfh generation in the absence of TP—despite increased expansion—likely reflects the constant pattern of effector cell differentiation inherent to OT-II TCR transgenic CD4+ cells (Tubo et al., 2013). Germinal center (GC) B cells showed a parallel increased expansion in TP−/− as compared with WT OT-II CD4+ T cell recipients (Fig. 4, G and H; and Fig. S1 E). Collectively, using a monoclonal CD4+ T cell population, we identified a negative regulatory role of TP for weak T cell–DC interactions induced by limited amounts of cognate pMHC or APL presentation. The absence of TP on pMHC-specific transferred CD4+ T cells sufficed to produce a substantial increase in Tfh and, as a consequence, GC B cells during inflammation.

Increased Tfh numbers in the absence of TP correlate with low-affinity IgG production

We investigated the functional consequences of TP−/− Tfh accumulation on the quality of ensuing IgG responses. We adaptively transferred WT or TP−/− OT-II CD4+ T cells into SMARTA mice, in which the majority of CD4+ T cells are specific for the LCMVgp61-80 peptide and therefore unable to provide B cell help to other epitopes in the first 8 d after immunization (Oxenius et al., 1998; and unpublished data). After immunization with NP68-BSA, low-affinity IgG response was analyzed on day 8 serum titer of high- and low-affinity IgG by ELISA using NP68- or NP68-BSA-coated plates, respectively. We found that although both WT and TP−/− OT-II CD4+ T cells were able to support similar titers of high-affinity IgG against NP68-BSA, low-affinity anti-NP68-BSA IgG production was substantially increased in SMARTA recipients transferred with TP−/− OT-II CD4+ T cells (Fig. 5, A and B). Finally, we transferred OVA tet+ CD4+
T cells isolated from OVA-immunized WT and TP−/− mice into SMARTA mice and challenged the recipients with NP16-OVA as above (Fig. S1 F). Again, we observed that mice transferred with TP−/− OVA tet+ CD4+ T cells showed skewing of the ensuing IgG response to low-affinity IgG compared with WT OVA tet+ CD4+ T cells, as reflected by a substantial increase in titers of NP41− but not NP8-BSA–binding IgG (Fig. 5 C). In sum, these data support a scenario where absence of TP leads to a significant rise in Tfh expansion, which has been associated with decreased quality of humoral responses (Pratama and Vinuesa, 2014). Alternatively, owing to their avid binding to cells bearing low pMHC levels, activated TP−/− CD4+ Tfh cells, or their precursors, may provide help to B cells with low-affinity BCRs. To address this point experimentally, we used 2PM of HEL-OVA–draining PLNs to examine WT and TP−/− OT-II CD4+ T cell interactions with HEL-specific MD4 or SWHEL B cells at the border between T cell area and B cell follicles, where early CD4+ T cell–B cell interactions (1–3 d after immunization) precede ensuing GC reactions (Vinuesa and Cyster, 2011). Although most T cell–B cell interactions were short-lived in these experiments (<5 min), we found occasional long interactions (>20 min) exclusively in the TP−/− CD4+ T cell subset (unpublished data). However, because TP−/− OT-II CD4+ T cells show increased expression of activation markers at early time points and the cognate pMHC density on individual B cells was unknown, these data remain difficult to interpret. Furthermore, 2PM experiments at later time points after immunization showed that TP antagonist GR32191B treatment did not reduce speeds of Ag-specific CD4+ T cells migrating along FDCs (unpublished data). In line with this, TP expression decreases on effector T cells, including Tfh, and B cells do not express TXA2 synthase and do not secrete TXA2 (Immgen database; unpublished data; Kabashima et al., 2003). Recent evidence has uncovered that Tfh interact with GC B cells for only a short period of time, even when these cells present high levels of cognate pMHC (Shulman et al., 2014). It is therefore conceivable that excessive numbers of Tfh provide help to numerous GC B cells, which then drives production of low-affinity IgG. In line with this concept, Tfh help for cognate Ag-bearing GC B cells directly correlates with...
their expansion (Shulman et al., 2013; Gitlin et al., 2014) and unrestrained T<sup>FH</sup> numbers are associated with autoimmunity and self-reactive B cells (Pratama and Vinuesa, 2014). This is likely to contribute to the development of lymphoid hyperplasia in older T<sup>P–/–</sup> mice (Kabashima et al., 2003), perhaps owing to excessive immune reactions to commensals in line with our observation of increased MLN size in these mice.

Immunoregulatory mechanisms need to be carefully balanced to simultaneously allow for a forceful adaptive immune response against pathogens to develop, while protecting the host from autoreactive T cells. How such a balance is achieved is not completely understood to date. Although immunosuppressive mechanisms have often been considered to generally hamper immune responses, Pace et al. (2012) have uncovered improved CD8<sup>+</sup> T cell avidity in the presence of T<sup>reg</sup> cells. Similarly, we report that absence of TP increased the numbers of low-avidity CD4<sup>+</sup> T cell clones transiting from kynapse- to synapse-like interactions with DCs (Bousso, 2008). In contrast to T<sup>reg</sup> cells or stromal cell–derived nitric oxide (Łukacs-Kornek et al., 2011), which typically function...
Thromboxane A2 controls CD4+ T cell avidity | Moalli et al.

**Figure 5.** TP−/− CD4+ T cells preferentially support low-avidity IgG responses. WT or TP−/− OT-II CD4+ T cells (A and B) or OVA-tet WT or TP−/− CD4+ T cells (C) were adoptively transferred into SMARTA recipients before immunization with NP87-OVA/CFA. On day 8 after infection, serum was isolated and IgG titers against NP87-BSA and NP41-BSA were measured in limited dilution assays. (A) Each line presents a dilution series of serum isolated from an individual mouse. (B) IgG titers to NP87- and NP41-BSA after transfer of WT or TP−/− OT-II CD4+ T cells. (C) IgG titers to NP87- and NP41-BSA after transfer of OVA-tet+ WT or TP−/− CD4+ T cells. Data in B and C are pooled from two independent experiments with 4–5 mice/group and analyzed by ANOVA with Sidak’s multiple comparison test. **, P < 0.01; ***, P < 0.001.

**Materials and Methods**

**Mice.** 4–6-wk-old male C57BL/6 mice were purchased from Janvier (AD Horiz). LCMV gp61-80-specific Tg[TcrL2M4]/Aox−/− (“SMARTA”), C57BL/6-Tg(CAG-EGFP)131Osb/LeySopJ (“Ubi-GFP”), Tg[Igh/MD4]4Ccg BCR-transgenic “MD4” (provided by E. Jacque, National institute for Medical Research, London, UK), C57BL/6-Tg[ghkHyHEL10]1Bhr (“SWIHEL”; provided by B. Stolp, University of Heidelberg, Germany), and TP−/− mice on a C57BL/6 background backcrossed to OT-II TCR transgenic mice for chicken OVA amino acids 323–339 were bred in the DKF animal facility in Bern. Animal work has been approved by the Cantonal Committee for Animal Experimentation and conducted according to federal and cantonal guidelines. Infection experiments were performed in accordance with federal and cantonal guidelines under permission numbers SG13/06/after review and approval by the Cantonal Veterinary Office (St. Gallen, Switzerland).

**TP antagonist treatment and tetramer staining after OVA-CFA immunization.** WT or TP−/− mice were immunized with chicken OVA/CFA emulsion (1 mg/ml; Sigma-Aldrich) injected s.c. in a volume of 30 µl/site in five points closed to inguinal, brachial, and cervical PLNs. In some experiments, WT mice were treated with a selective thromboxane receptor antagonist, GR32191B (Vapiprost, Sigma-Aldrich), in drinking water for 9 d, starting 1 d before OVA-CFA immunization, at a dose of 1 mg/kg/d. Mice were killed after 8 d, as described above, and tetramer staining was performed using the following tetramers (produced by National Institutes of Health Tetramer Core Facility, Atlanta, GA), diluted 1:10, for 2 h at 37°C: PVSKMWRMATPLMQLA-PE-control (human CLIP(101-113)), HAA-HAEINEA-PE-chicken OVA228-235 (tetramer 1), INFKELTKTSSNVMEER-PE-chicken OVA259-277 (tetramer 2), and AAHAHAEINEA-PE chicken OVA262-270 (tetramer 3). All three OVA tetramers gave comparable results in flow cytometry.

Neutrophils were depleted by administration of the Ly6G-specific 1A8 mAb as previously described (Yang and Unanue, 2013), starting on day −1 before immunization and reinjected every 2 d. An isotype-matched mAb (2A3) was used as control. Depletion was verified by flow cytometry.
LCMV infection and flow cytometry analysis. LCMV strains Armstrong and Clone 13 were propagated on L929 cells and titrated by focus-forming assay on MC57 cells. Mice were infected i.v. with 10^3 PFU LCMV Armstrong or 10^3 PFU LCMV Clone 13. For flow cytometry, mice were sacrificed on day 8 after infection and single-cell suspensions from spleen and inguinal LNs were prepared by mechanical disruption of the organs. Analysis of LCMV-specific CD8^+ T cells was performed using PE-conjugated tetramers against LCMV gp34-31 and for CD4^+ T cell responses gp35-37. We used as negative control the LCMV gp precursor p30 tetramer. MHC class II tetramer staining was performed for 90 min at 37°C. For surface staining, allophycocyanin-labeled anti-CD4 (BD) was used. Surface staining was performed by incubating samples at 4°C for 20 min 7-Aminoactinomycin D (EMD Millipore) was used to discriminate dead cells in flow cytometric analysis. Foxp3 staining was performed with the mouse regulatory T cell staining kit (eBioscience) using the Foxp3 PE (FJK-161) mAb. Samples were analyzed by flow cytometry using FACS-Calibur (BD), and data were analyzed using FlowJo software (Tree Star).

T cell purification. LNs and spleens from WT or TP^-/- mice were pooled and homogenized using a 70-µm strainer. Red blood cells were lysed in 1 ml of a Tris-HCl pH 7.5/0.83% ammonium-chloride buffer for 3 min. After washing in CM-R, a medium containing RPMI-1640 supplemented with 10% FCS, 100 U/ml penicillin, 100 U/ml streptomycin, 100 mM sodium pyruvate, L-glutamine, and nonessential amino acids (NEAA), we used EasySep Mouse T cell Negative Selection kit or Mouse CD4^+ T cell enrichment kit as described in the manufacturer’s instructions (STEMCELL Technologies). Total or CD4^+ T cells were negatively isolated in a magnetic holder. CD4^+ T cell purities were typically >95%.

DC culture and peptide pulsing. BM cell suspensions from Ubi-GFP mice were obtained by centrifugation (4,000 rpm, 4 min) of femurs and tibiae. BM cells were incubated in 20 ml cultures containing 18 ml CM-R and 2 ml SP-20 supernatant containing Flt3L for 6 to 9 d until activation with 1 µg/ml LPS (Sigma-Aldrich) for 24 h and pulsing with OVA peptides for 1 h at 37°C. Chicken OVA(323-339) (SQAVHAAHAELNEAGR) and turkey OVA(256-340) (ISQAHAYEAIEYAGR) were obtained from Eurogentec.

2PM of popliteal PLNs. GFP-expressing DCs (2 × 10^5/mouse) were pulsed with indicated concentrations of chicken or turkey OVA peptide and injected i.v. in hindfoot of recipient mice 18 h before CD4^+ T cell transfer. Purified T cells were fluorescently labeled with 2.5 µM CMTMR or 20 µM CMAC for 15 min at 37°C, with dyes swapped between experiments. After washing, 5 × 10^5 labeled T cells were injected i.v. into sex-matched 5–10-wk-old anesthetized C57BL/6 recipients for 30 min. 5 × 10^6 labeled T cells were injected i.v. into sex-matched C57BL/6 recipients. Alternatively, 5 × 10^6 CD4^+ or CD8^+ T cells were separately transferred into sex-matched C57BL/6 recipients. The day after cell transfer, mice were immunized with chicken OVA/CFA emulsion (1 mg/ml) (Sigma-Aldrich) injected s.c. in a volume of 30 µl/site in five points closed to inguinal, brachial and cervical PLNs. Recipients were killed after 8 d and cells from cervical, brachial, and inguinal nodes were pooled. Cell surface stainings were performed in staining buffer for 30 min with the appropriate combinations of saturating concentrations of the following conjugated mAbs obtained from BioLegend: CD25 (3C7), CD69 (H1.2F3), and CD4 (GK1.5). Flow cytometry was performed on a FACS-Calibur (BD) and FlowJo software (Tree Star) for analysis.

Flow cytometry for activation markers. WT and TP^-/- OT-II CD4^+ T cells were labeled with CFSE or e670 and analyzed 24 h after transfer into mice with pMHc-bearing DCs as described for 2PM experiments. Cell surface stainings were performed in staining buffer (PBS containing 1% FCS) for 30 min on ice in the dark, with the appropriate combinations of saturating concentrations of the following conjugated mAbs obtained from BioLegend: CD25 (3C7), CD69 (H1.2F3), and CD4 (GK1.5). Flow cytometry was performed on a FACS-Calibur (BD) and FlowJo software (Tree Star) for analysis.

T cell transfer. 5 or 18–22 h after T cell transfer, 2PM imaging was performed by incubating samples at 4°C for 20 min 7-Aminoactinomycin D (EMD Millipore) was used to discriminate dead cells in flow cytometric analysis. Foxp3 staining was performed with the mouse regulatory T cell staining kit (eBioscience) using the Foxp3 PE (FJK-161) mAb. Samples were analyzed by flow cytometry using FACS-Calibur (BD), and data were analyzed using FlowJo software (Tree Star).

IgG titration. WT and TP^-/- mice were immunized with chicken OVA/CFA emulsion as above, followed by staining with OVA tetramer 2 and FITC-conjugated anti-CD4 mAb (1:15,000 dilution to avoid depletion after transfer). Low and high tet^+ populations were sorted on a FACS Aria II Flow Cytometer (BD), and 5 × 10^6 tet^+ low WT or TP^-/- CD4^+ T cells were separately transferred into sex-matched SMARTA recipients. Owing to low numbers of recovered cells, we did not perform adoptive transfer of OVA tet^+ high CD4^+ T cells. Alternatively, 5 × 10^6 OT-II WT or TP^-/- CD4^+ T cells were separately transferred into sex-matched SMARTA recipients. The day after cell transfer, mice were immunized with NP_63-77 OVA (1 mg/ml) (Sigma-Aldrich) injected s.c. in a volume of 30 µl/site in five points closed to inguinal, brachial and cervical PLNs. Recipients were killed after 8 d and cells from cervical, brachial, and inguinal nodes were pooled. Cell surface stainings were performed in staining buffer for 30 min with the appropriate combinations of saturating concentrations of the following conjugated mAbs obtained from BD, eBioscience, or BioLegend: CD45.2 (104), CD45.1 (A20), Gl-7 (GL-7), PD-1 (29F.1A12), ICOS (C398.4A), OX-40 (OX-86), Ly6C (HK1.4), PSGL-1, CD4 (RM4-5), CD45R (RA3-6B2), IgD (11-26c.2a), biotinylated CXCR5 (SPR.CLS), followed by BV605-streptavidin, and biotinylated CD95, followed by BV421-streptavidin. In some experiments, cells were permeabilized using Cytofix/Cytoperm solution (BD) for staining with anti-IL-21 mAb (BL25168; BioLegend) or permeabilized with Foxp3 buffer for bc36 (K112-91; BD) or Foxp3 (FJK-16C; eBioscience) staining according to manufacturer’s instructions to confirm that adoptively transferred OT-II CD4^+ T cells do not form follicular regulatory T cells (Linterman et al., 2011). Stained cells were analyzed with LSR II or FACS Calibur flow cytometer (BD). Diva software or CellQuest were used for data acquisition, FlowJo software (Tree Star) was used for data analysis.

IgG titration. WT and TP^-/- mice were immunized with chicken OVA/CFA emulsion as above, followed by staining with OVA tetramer 2 and FITC-conjugated anti-CD4 mAb (1:15,000 dilution to avoid depletion after transfer). Low and high tet^+ populations were sorted on a FACS Aria II Flow Cytometer (BD), and 5 × 10^6 tet^+ low WT or TP^-/- CD4^+ T cells were separately transferred into sex-matched SMARTA recipients. Owing to low numbers of recovered cells, we did not perform adoptive transfer of OVA tet^+ high CD4^+ T cells. Alternatively, 5 × 10^6 OT-II WT or TP^-/- CD4^+ T cells were separately transferred into sex-matched SMARTA recipients. The day after cell transfer, mice were immunized with NP_63-77 OVA/CFA emulsion (1 mg/ml) (Sigma-Aldrich) injected s.c. in a volume of 30 µl/site in five points closed to inguinal, brachial and cervical PLNs. Recipients were killed after 8 d and cells from cervical, brachial, and inguinal nodes were pooled. Cell surface stainings were performed in staining buffer for 30 min with the appropriate combinations of saturating concentrations of the following conjugated mAbs obtained from BD, eBioscience, or BioLegend: CD45.2 (104), CD45.1 (A20), Gl-7 (GL-7), PD-1 (29F.1A12), ICOS (C398.4A), OX-40 (OX-86), Ly6C (HK1.4), PSGL-1, CD4 (RM4-5), CD45R (RA3-6B2), IgD (11-26c.2a), biotinylated CXCR5 (SPR.CLS), followed by BV605-streptavidin, and biotinylated CD95, followed by BV421-streptavidin. In some experiments, cells were permeabilized using Cytofix/Cytoperm solution (BD) for staining with anti-IL-21 mAb (BL25168; BioLegend) or permeabilized with Foxp3 buffer for bc36 (K112-91; BD) or Foxp3 (FJK-16C; eBioscience) staining according to manufacturer’s instructions to confirm that adoptively transferred OT-II CD4^+ T cells do not form follicular regulatory T cells (Linterman et al., 2011). Stained cells were analyzed with LSR II or FACS Calibur flow cytometer (BD). Diva software or CellQuest were used for data acquisition, FlowJo software (Tree Star) was used for data analysis.
at 37°C. After washing with WB, biotinylated polyclonal goat anti-mouse IgG (10 ng/well; AbD Serotec) diluted in WB was added for 1 h at room temperature. Wells were washed and incubated for 1 h at room temperature with 100 μl streptavidin-HRP (AbD Serotec) diluted 1/1,000 in WB. Bound antibodies were detected using OPD substrate, and absorbance was read at a wavelength of 490 nm. Results were calculated as titer by interpolation of absorbance values at a fixed serum dilution into a linear regression analysis plotting. Owing to the high molar ratio of NP moieties to BSA in the NP-μg-BSA coated plates, low-and high-affinity anti-NP mAbs can bind, whereas only high affinity anti-NP mAbs bind to NP-μg-BSA-coated plates.

Statistical analysis. Data were analyzed with GraphPad Prism 6 using Mann-Whitney test or ANOVA-one way test followed by Bonferroni’s or Sidak’s multiple comparison test. P values >0.05 were considered not significant.

Online supplemental material. Videos 1–6 show the dynamic interactions of OT-II CD4+ T cells with DCs pulsed with 0.1 μM OVA, 10 μM OVA, and 10 μM OVA. Fig. S1 shows the gating strategies used for flow cytometric analysis. Online supplemental materials are available at http://www.jem.org/cgi/content/full/jem.20140137/DC1.

We thank Markus Ackerknecht for advice on experiments, Bettina Stolp for SW6-ΔΔ mice, Emilie Jacque for MD4 mice, Milan Kubicek for scripts, Kenji Kabashima for discussion, Sarah Henrickson and Ulrich H. von Andrian for MatLab scripts, and Marcus Thelen and Britta Engelhardt for continuous support. We acknowledge the support from the Flow Cytometry core unit at the Department for Clinical Research. All tetramers were from the National Institutes of Health tetramer core facility.

This work was supported by SNF grant 31003A_135649 (to JVS), SNF Sinergia grant CRSII3_141918 (to BL and JVS), a Japanese-Swiss Science and Technology Program grant (to YF and JVS), the Italian Association for Cancer Research (AIRC), and the Bangerter Foundation (to FM).

The authors declare no competing financial interests.

Submitted: 22 January 2014
Accepted: 5 November 2014

REFERENCES


